Yves Fradet

List of Publications by Year
in descending order

38 papers	3,763 citations	430874 18 h-index	345221 36 g-index
39 all docs	39 docs citations	39 times ranked	6256 citing authors

#	Article	IF	Citations
1	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 1015-1026.	27.0	2,677
2	CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy. Cancer Research, 2015, 75, 950-962.	0.9	150
3	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. European Urology, 2014, 66, 361-370.	1.9	125
4	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology, 2018, 36, 1579-1587.	1.6	97
5	Dietary fat and prostate cancer survival. Cancer Causes and Control, 1999, 10, 245-251.	1.8	93
6	Dietary energy and nutrients in relation to preclinical prostate cancer. Nutrition and Cancer, 1997, 29, 120-126.	2.0	67
7	Canadian Urological Association guideline: Muscle-invasive bladder cancer. Canadian Urological Association Journal, 2018, 13, 230-238.	0.6	51
8	Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. Prostate, 2019, 79, 1767-1776.	2.3	51
9	FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging, 2015, 15, 2.	2.8	47
10	Lifetime occupational physical activity and incidental prostate cancer (Canada). Cancer Causes and Control, 2000, 11, 759-764.	1.8	41
11	Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Current Opinion in Urology, 2009, 19, 243-246.	1.8	40
12	The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. European Urology, 2016, 69, 601-609.	1.9	36
13	Omegaâ€3 fatty acids decrease prostate cancer progression associated with an antiâ€tumor immune response in eugonadal and castrated mice. Prostate, 2019, 79, 9-20.	2.3	28
14	IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. Research and Reports in Urology, 2014, 6, 27.	1.0	26
15	Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8â€"10 Prostate Cancers Identifies Very Highâ€"risk Patients for Early Recurrence and Resistance to Castration. European Urology Focus, 2019, 5, 998-1006.	3.1	25
16	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	7.0	21
17	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy caseâ€"control study with multicohort validation. PLoS Medicine, 2020, 17, e1003281.	8.4	19
18	Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. Radiation Oncology, 2019, 14, 60.	2.7	18

#	Article	IF	Citations
19	Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 363.e7-363.e11.	1.6	16
20	Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. European Urology Focus, 2017, 3, 639-642.	3.1	15
21	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial. Clinical Cancer Research, 2018, 24, 5305-5312.	7.0	13
22	A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association Journal, 2020, 14, 319-321.	0.6	11
23	Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study. Nutrition and Cancer, 2017, 69, 1196-1204.	2.0	10
24	Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. Molecular Cancer Research, 2021, 19, 516-527.	3.4	10
25	Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?. Clinical Genitourinary Cancer, 2019, 17, e1122-e1128.	1.9	9
26	Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. World Journal of Urology, 2021, 39, 1549-1558.	2.2	9
27	Recent advances in the management of superficial bladder tumors. Canadian Journal of Urology, 2002, 9, 1544-50.	0.0	7
28	Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine Connections, 2019, 8, 132-140.	1.9	6
29	Arguments against investing widely in robotic prostatectomy in Canada: a wrong focus on tool box rather than surgical expertise. Canadian Urological Association Journal, 2013, 3, 486.	0.6	5
30	Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review. Canadian Urological Association Journal, 2017, 11, 419-24.	0.6	5
31	Does 5-alpha Reductase Inhibitor Use Improve The Efficacy of Intravesical Bacille Calmette-GuÃ©rin (BCG) for Non-muscle Invasive Bladder Cancer?. Bladder Cancer, 2020, 6, 63-69.	0.4	5
32	Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of Biomedical Optics, 2021, 26, .	2.6	4
33	Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. Asian Journal of Andrology, 2022, 24, 21.	1.6	2
34	Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. Clinical Nutrition ESPEN, 2022, 47, 221-226.	1.2	2
35	Assembling a network to promote translational bladder cancer research in Canada. Canadian Urological Association Journal, 2020, 14, E475-E481.	0.6	1
36	Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis.. Journal of Clinical Oncology, 2012, 30, 443-443.	1.6	0

#	Article	IF	Citations
37	Invasive bladder cancer: time is of the essence. Canadian Urological Association Journal, 2013, 2, 109.	0.6	0
38	Role of radical prostatectomy in high-risk prostate cancer. Canadian Journal of Urology, 2002, 9 Suppl 1, 8-13.	0.0	0